Based on this, our study systematically explored TLR9 expression in B-ALL, providing insight into the direct effects of CpG ODNs in B-ALL with different characteristics, and proposed TLR9 as a potential target for B-ALL treatment. Here, TLR9 is linked to acute lymphoblastic leukemia.